1,729 reports of this reaction
1.7% of all RIOCIGUAT reports
#14 most reported adverse reaction
FLUID RETENTION is the #14 most commonly reported adverse reaction for RIOCIGUAT, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 1,729 FDA adverse event reports linking RIOCIGUAT to FLUID RETENTION. This represents approximately 1.7% of all 100,865 adverse event reports for this drug.
RIOCIGUAT has an overall safety score of 85 out of 100. Patients taking RIOCIGUAT who experience fluid retention should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FLUID RETENTION is a less commonly reported adverse event for RIOCIGUAT, but still significant enough to appear in the safety profile.
In addition to fluid retention, the following adverse reactions have been reported for RIOCIGUAT:
The following drugs have also been linked to fluid retention in FDA adverse event reports:
FLUID RETENTION has been reported as an adverse event in 1,729 FDA reports for RIOCIGUAT. This does not prove causation, but indicates an association observed in post-market surveillance data.
FLUID RETENTION accounts for approximately 1.7% of all adverse event reports for RIOCIGUAT, making it a notable side effect.
If you experience fluid retention while taking RIOCIGUAT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.